This month’s cover story, entitled “Dubious Treatments, ‘Snake Oil Salesmen’ Grab Attention in Rheumatology,” features a ...

Discover why Genmab A/S stands out as a high-margin biotech with strong partnerships, robust growth prospects, and ...

J&J JNJ announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended granting label expansion ...

The Glioblastoma Treatment Drugs Market is projected to generate USD 844.8 million in revenues by 2025 and is expected to ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase I/II data on NXT007 in people with haemophilia A, supporting its progression into phase III clinical development. NXT007 is a ...

Even though the Central government had revised the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) for the pharma industry last year, it remains toothless and statutorily unbinding, ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products ...

Citi analyst Geoff Meacham maintained a Hold rating on AbbVie (ABBV – Research Report) today. The company’s shares closed last Wednesday at $185.49. Confident Investing Starts ...

According to TipRanks, Breen is a 2-star analyst with an average return of 1.4% and a 42.86% success rate. Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Moderna, and ...

AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, ...

In the US, patients diagnosed with noninfectious uveitis (NIU) are higher in number than infectious uveitis (IU). In 2022, ...

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with ...